SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) are effective for T2DM and CKD; ongoing trials are examining their direct effects on NAFLD [16]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.